Theralase Technologies Inc.

As of June 30, 2026, Theralase Technologies Inc. carries a market capitalization of 75.40M, placing it among publicly traded companies globally. Its enterprise value stands at 70.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Theralase Technologies Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Theralase Technologies Inc. has 295.67M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 84.60, and the price-to-book ratio stands at 11.02.

These figures are as of June 30, 2026. The EV/Sales ratio of 87.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 70.28M versus a market cap of 75.40M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Theralase Technologies Inc. maintains a current ratio of 5.48, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.17, indicating elevated leverage, while an interest coverage ratio of -59.16 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Theralase Technologies Inc. posted a negative return on equity (ROE) of -93.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -68.06, reflecting losses generated across the asset base. The company generates approximately 50,153.88 in revenue per employee across its workforce of 16.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.56 indicates how many times Theralase Technologies Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Theralase Technologies Inc.'s stock has gained approximately 4.88% over the past 52 weeks. The 50-day moving average sits at 0.21, while the 200-day moving average is 0.23.

Over the twelve months ended June 30, 2026, Theralase Technologies Inc. generated 802,462.00 in revenue and converted that into -3.79M in net income, yielding earnings per share of -0.01. EBITDA reached -3.56M, while operating income came in at -3.81M.

As of June 30, 2026, Theralase Technologies Inc. holds 5.26M in cash and equivalents against 148,717.00 in total debt, resulting in a net debt position of -5.26M. Total book value stands at 6.84M, with working capital of 5.59M providing operational flexibility.

Theralase Technologies Inc. produced -3.39M in operating cash flow over the twelve months ended June 30, 2026. After subtracting 21,445.00 in capital expenditures, free cash flow totaled -3.37M - equivalent to -0.01 per share.

Over the twelve months ended June 30, 2026, Theralase Technologies Inc. posted a gross margin of 65.44, reflecting its pricing power and cost economics. The operating margin of -474.33 and net profit margin of -472.48 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.96: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -11.38, meaning Theralase Technologies Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Theralase Technologies Inc. has an Altman Z-Score of 21.91, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.